Cargando…
Update and critical appraisal of sevelamer in the management of chronic renal failure
Sevelamer (Renagel and Renvela), is an orally administered weakly basic anion exchange resin that binds dietary phosphate in the gastrointestinal tract, and is approved for use in the US, Europe and many other countries for the treatment of hyperphosphatemia in adult patients on hemodialysis or peri...
Autores principales: | Grinfeld, Jacob, Inaba, Akimichi, Hutchison, Alastair J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818887/ https://www.ncbi.nlm.nih.gov/pubmed/24198624 http://dx.doi.org/10.2147/OAJU.S7227 |
Ejemplares similares
-
Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients
por: Ossareh, Shahrzad
Publicado: (2014) -
Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008) -
Chronic Renal Failure and Cardiovascular Disease: A Comprehensive Appraisal
por: Skalsky, Keren, et al.
Publicado: (2022) -
Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease
por: Rastogi, Anjay
Publicado: (2013) -
A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis
por: Fan, Stanley, et al.
Publicado: (2009)